-transparent.png){kind=logo}
The pharmacokinetic parameters of cefpirome (HR 810) were examined in 22 patients with different degrees of renal impairment. HPLC was used to analyze samples of blood and urine for cefpirome; and enzymatic assay of creatinine in serum and urine was used to assess kidney function. Creatinine clearance correlated linearly with both total and renal clearance of cefpirome. The loss of kidney function resulted in a decreased renal clearance, whereas the volume of distribution remained the same. This result led to an increase in the terminal half-life of the drug, from 2 hours in healthy subjects to 14 1/2 hours in patients with uremia. This increase also resulted in a prolonged high serum concentration well above the minimum inhibitory concentration. The following dosages are thus recommended: (1) creatinine clearance greater than 50 ml/min: normal daily dose, (2) creatinine clearance from 20 to 50 ml/min: 50% of normal daily dose, and (3) creatinine clearance less than 20 ml/min: 25% of normal daily dose. An initial loading dose of 1 gm, independent of renal function, is advised. Cefpirome was safe and well tolerated.
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
February 2014,
International journal of clinical pharmacology and therapeutics,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
February 1992,
Journal of clinical pharmacology,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
March 2016,
Pulmonary circulation,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
August 2013,
Drug discoveries & therapeutics,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
December 1991,
Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
October 2018,
Clinical therapeutics,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
May 2000,
Progress in neuro-psychopharmacology & biological psychiatry,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
January 1990,
European journal of drug metabolism and pharmacokinetics,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
May 2001,
European journal of clinical pharmacology,
N Lameire, and
V Malerczyk, and
B Drees, and
K Lehr, and
B Rosenkranz
January 2015,
Antiviral therapy,
